Vortioxetine
|
- ₹0
- Product name: Vortioxetine
- CAS: 508233-74-7
- MF: C18H22N2S
- MW: 298.45
- EINECS:823-919-6
- MDL Number:MFCD22380814
- Synonyms:Trintellix (vortioxetine);Vortioxetine(Lu AA21004);1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)PIPERAZINE-HCL;Vortioxetine, >=99%;Lu AA 21004;Vortioxetine;1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine;Vortioxetine ?LuAA21004 ? 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Melting point :115-117°C
Boiling point :424.8±45.0 °C(Predicted)
Density :1.16
storage temp. :-20°C Freezer
solubility :DMSO (Slightly), Methanol (Slightly)
pka :8.85±0.10(Predicted)
form :Solid
color :White to Off-White
InChI :InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
InChIKey :YQNWZWMKLDQSAC-UHFFFAOYSA-N
SMILES :N1(C2=CC=CC=C2SC2=CC=C(C)C=C2C)CCNCC1
Boiling point :424.8±45.0 °C(Predicted)
Density :1.16
storage temp. :-20°C Freezer
solubility :DMSO (Slightly), Methanol (Slightly)
pka :8.85±0.10(Predicted)
form :Solid
color :White to Off-White
InChI :InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
InChIKey :YQNWZWMKLDQSAC-UHFFFAOYSA-N
SMILES :N1(C2=CC=CC=C2SC2=CC=C(C)C=C2C)CCNCC1
Safety Information
| Symbol(GHS): |
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||||||||||||||||
| Hazard statements: |
|
||||||||||||||||||||||||||||
| Precautionary statements: |
|
Description
Vortioxetine (Brintellix) is an antidepressant that works through serotonin reuptake inhibition and direct receptor activity, acting as both a serotonin receptor agonist and antagonist.It is labeled for the treatment of major depressive disorder in adults.Brintellix/Trintellix (vortioxetine) is approved for the treatment of major depressive disorder (MDD). Sales grew 10% (13% in local currencies) reaching DKK 3,102 million. The regional distribution of sales was 54%, 19% and 27% in North America, International Markets and Europe, respectively. The largest markets for the product are the U.S., Canada, Spain, Italy and Brazil. Brintellix/Trintellix has especially in the second half been impacted by the reduced promotional activity in many countries as a consequence of the COVID-19 pandemic thereby having impacted new patient enrolment negatively, particularly among primary care physicians (PCPs).
Related product price
- Voriconazole
₹10500-63477.8 - Celecoxib
₹2600-36707.58 - 2,4-Dimethylbenzenethiol
₹2800-10381.18